tetano
Editor, Senior Moderator
Virus Res
. 2023 Sep 11;199221.
doi: 10.1016/j.virusres.2023.199221. Online ahead of print. Suramin inhibits SARS-CoV-2 nucleocapsid phosphoprotein genome packaging function
Irene Boniardi[SUP] 1 [/SUP], Angela Corona[SUP] 2 [/SUP], Jerome Basquin[SUP] 3 [/SUP], Claire Basquin[SUP] 3 [/SUP], Jessica Milia[SUP] 2 [/SUP], István Nagy[SUP] 4 [/SUP], Enzo Tramontano[SUP] 5 [/SUP], Luca Zinzula[SUP] 6 [/SUP]
Affiliations
The coronavirus disease 2019 (COVID-19) pandemic is fading, however its etiologic agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues posing - despite the availability of licensed vaccines - a global health threat, due to the potential emergence of vaccine-resistant SARS-CoV-2 variants. This makes the development of new drugs against COVID-19 a persistent urgency and sets as research priority the validation of novel therapeutic targets within the SARS-CoV-2 proteome. Among these, a promising one is the SARS-CoV-2 nucleocapsid (N) phosphoprotein, a major structural component of the virion with indispensable role in packaging the viral genome into a ribonucleoprotein (RNP) complex, which also contributes to SARS-CoV-2 innate immune evasion by inhibiting the host cell type-I interferon (IFN-I) response. By combining miniaturized differential scanning fluorimetry with microscale thermophoresis, we found that the 100-year-old drug Suramin interacts with SARS-CoV-2 N N-terminal domain (NTD) and C-terminal domain (CTD), thereby inhibiting their single-stranded RNA (ssRNA) binding function with low-micromolar K[SUB]d[/SUB] and IC[SUB]50[/SUB] values. Molecular docking suggests that Suramin interacts with basic NTD cleft and CTD dimer interface groove, highlighting three potentially druggable ssRNA binding sites. Electron microscopy shows that Suramin inhibits the formation in vitro of RNP complex-like condensates by SARS-CoV-2 N with a synthetic ssRNA. In a dose-dependent manner, Suramin also reduced SARS-CoV-2-induced cytopathic effect on Vero E6 and Calu-3 cells, partially reverting the SARS-CoV-2 N-inhibited IFN-I production in 293T cells. Our findings indicate that Suramin inhibits SARS-CoV-2 replication by hampering viral genome packaging, thereby representing a starting model for design of new COVID-19 antivirals.
Keywords: COVID-19; SARS-CoV-2; Suramin; antiviral agents; nucleocapsid phosphoprotein; viral replication.
. 2023 Sep 11;199221.
doi: 10.1016/j.virusres.2023.199221. Online ahead of print. Suramin inhibits SARS-CoV-2 nucleocapsid phosphoprotein genome packaging function
Irene Boniardi[SUP] 1 [/SUP], Angela Corona[SUP] 2 [/SUP], Jerome Basquin[SUP] 3 [/SUP], Claire Basquin[SUP] 3 [/SUP], Jessica Milia[SUP] 2 [/SUP], István Nagy[SUP] 4 [/SUP], Enzo Tramontano[SUP] 5 [/SUP], Luca Zinzula[SUP] 6 [/SUP]
Affiliations
- PMID: 37704176
- DOI: 10.1016/j.virusres.2023.199221
The coronavirus disease 2019 (COVID-19) pandemic is fading, however its etiologic agent severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) continues posing - despite the availability of licensed vaccines - a global health threat, due to the potential emergence of vaccine-resistant SARS-CoV-2 variants. This makes the development of new drugs against COVID-19 a persistent urgency and sets as research priority the validation of novel therapeutic targets within the SARS-CoV-2 proteome. Among these, a promising one is the SARS-CoV-2 nucleocapsid (N) phosphoprotein, a major structural component of the virion with indispensable role in packaging the viral genome into a ribonucleoprotein (RNP) complex, which also contributes to SARS-CoV-2 innate immune evasion by inhibiting the host cell type-I interferon (IFN-I) response. By combining miniaturized differential scanning fluorimetry with microscale thermophoresis, we found that the 100-year-old drug Suramin interacts with SARS-CoV-2 N N-terminal domain (NTD) and C-terminal domain (CTD), thereby inhibiting their single-stranded RNA (ssRNA) binding function with low-micromolar K[SUB]d[/SUB] and IC[SUB]50[/SUB] values. Molecular docking suggests that Suramin interacts with basic NTD cleft and CTD dimer interface groove, highlighting three potentially druggable ssRNA binding sites. Electron microscopy shows that Suramin inhibits the formation in vitro of RNP complex-like condensates by SARS-CoV-2 N with a synthetic ssRNA. In a dose-dependent manner, Suramin also reduced SARS-CoV-2-induced cytopathic effect on Vero E6 and Calu-3 cells, partially reverting the SARS-CoV-2 N-inhibited IFN-I production in 293T cells. Our findings indicate that Suramin inhibits SARS-CoV-2 replication by hampering viral genome packaging, thereby representing a starting model for design of new COVID-19 antivirals.
Keywords: COVID-19; SARS-CoV-2; Suramin; antiviral agents; nucleocapsid phosphoprotein; viral replication.